Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Telesis Bio Inc

Pfizer, BioNTech and Moderna used mRNA to build effective Covid-19 vaccines in record time, a feat Sanofi is keen to build upon in the future.

Sanofi Buys U.S. Partner Translate Bio For $3.2 Billion As Pharma Giant Bets Big On mRNA Tech

Sanofi to acquire U.S.-based Translate Bio in deal valued at $3.2 billion

French drugmaker Sanofi said it had made a $3.2 billion offer to buy U.S. biotech company Translate Bio, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

Sanofi confirms $3.2 billion offer to buy U.S. biotech firm Translate Bio

-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi's recently announced  mRNA Center of Excellence --

Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development

PARIS (Reuters) -Sanofi has offered to buy U.S. biotech company Translate Bio, two sources familiar with the situation said on Monday, as the French drugmaker bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race.

Exclusive-Sanofi offers to buy U.S. mRNA partner Translate Bio -sources

Sanofi SA (SNY) CEO Paul Hudson on Q2 2021 Results - Earnings Call Transcript

Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.

Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised

Online availability of Sanofi's half-year financial report for 2021

Viatris

Shares of Viatris Inc. gained 3.3% in premarket trading on Thursday, the day after the Food and Drug Administration approved the first biosimilar verson of insulin glargine from Viatris and Biocon Biologics Ltd. Biocon is a privately held biopharma company based in India.

Viatris gets FDA approval of first biosimilar version of Sanofi's insulin Lantus

Sanofi SA (NASDAQ: SNY) has raised its 2021 profit forecast after its vaccines and blockbuster eczema treatment Dupixent helped boost second-quarter results. Q2 2021 sales grew 6.55 Y/Y to €8.7 billion (up 12.4% at CER), mainly driven by Dupixent and new oncology.

Sanofi Q2 Performance Benefits From Dupixent, Vaccines; Raises 2021 Profit Forecast

Regeneron Pharmaceuticals

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU), an inflammatory skin disease. The 138-subject study met its primary endpoints and all key secondary endpoints at 24 weeks.

Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients

Sanofi raised its 2021 outlook after its vaccines and star eczema treatment Dupixent helped it post better-than-expected second-quarter results on Thursday.

Sanofi raises profit forecasts after strong second quarter

Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sanofi SA's (NASDAQ: SNY) avalglucosidase alfa for Pompe disease. The positive opinion is based on Phase 3 COMET study data, which showed avalglucosidase alfa improved respiratory function and movement endurance measures.

Sanofi's Pompe Disease Enzyme Replacement Therapy Gets EMA's CHMP Backing

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all patients, and the data is pointing them towards former smokers. What Happened: A phase 2a study, published in The Lancet, showed that the companies' itepekimab, a monoclonal antibody lowered acute COPD exacerbations in former smokers.

Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers

Ashtead Group PLC

British American Tobacco

Diageo

EssilorLuxottica SA

Fresenius Medical Care

L'Oreal SA

Nestle SA

Novartis

Roche Holding AG

Unilever

Wolters Kluwer NV

Plenty of investors focus in on dividends, and dividend aristocrats, but if those investors only look in the U.S. they could be missing out. The post 15 European Dividend Aristocrats to Diversify Your Portfolio appeared first on InvestorPlace.

15 European Dividend Aristocrats to Diversify Your Portfolio

GlaxoSmithKline

EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NASDAQ: GSK), which started a 35,000-patient Phase 3 trial in May. The vaccine dubbed Vidprevtyn is based on a recombinant protein antigen developed by Sanofi and includes an immune-boosting adjuvant developed by GSK to boost its efficacy.

EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine

The FDA has approved Sanofi SA's (NASDAQ: SNY) fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness in patients six years of age and older and weighing at least 20 kg. Sleeping sickness is a parasitic disease transmitted by the bite of an infected tse-tse fly.

Sanofi's Oral Treatment For Sleeping Sickness Gets FDA Approval

Danone SA

LVMH Moet Hennessy Louis Vuitton

Orange

Bastille Day is France's National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept of revolution was a tad more boisterous than the American version — the Marquis de Launay, the governor of the Bastille, was decapitated by a butcher and his head was paraded through Paris on a spike — today's Bastille Day offers a colorful celebration of the noble concepts of liberty, equality and fraternity.

5 French Stocks To Consider For Bastille Day

Press release Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)

Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes?

Sanofi (SNY) is a Top Dividend Stock Right Now: Should You Buy?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Sanofi (SNY) Stock Undervalued Right Now?

Eli Lilly

The latest guideline update by the WHO includes the use of arthritis drugs like Roche's (RHHBY) Actemra and Sanofi's (SNY) Kevzara for the treatment of severe COVID-19.

WHO Guidelines Put Spotlight on Arthritis Drugs Actemra & Kevzara

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate. The companies in May started global trials to include more than 35,000 adults to test the candidate and hope to get approvals by the end of 2021.

Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India

The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients severely or critically ill with COVID-19 often suffer from an overreaction of the immune system.

News for Sanofi Stock (SNY)